FDA accepts BLA for fixed-dose combination of Perjeta + Herceptin with hyaluronidase, by subcutaneous injection in combination with I.V. chemotherapy for the treatment of HER2-positive breast cancer. Genentech/Roche
Related news and insights
Seagen Inc. announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of Tukysa (tucatinib) to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (MBC) with and without brain metastases.
Eli Lilly and Company announced patient-reported outcomes (PRO) for the investigational use of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC).